Study of Alpha-2 Adrenergic Receptor Dysfunction in Regional Lipoatrophy
OBJECTIVES: I. Determine the response in plasma norepinephrine concentration and plasma glycerol to the agonist (clonidine) and the antagonist (yohimbine) of the alpha-2 adrenergic receptor in 6 patients with regional lipoatrophy and in 6 controls.
II. Determine the full sequence of the alpha-2 adrenergic receptor structural gene in genomic DNA from peripheral blood leukocytes.
|Study Design:||Primary Purpose: Screening|
|Study Start Date:||November 1999|
PROTOCOL OUTLINE: Antihypertensives are held, beginning 3 days before the first study day.
An oral challenge is administered as follows: clonidine on day 1, yohimbine on day 2. The order of administration is reversed in alternate subjects.
Timed measurements of norepinephrine, glycerol, and free fatty acids follow each challenge. Structural gene sequencing is evaluated for each participant.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00004329
|United States, Texas|
|University of Texas Medical Branch|
|Galveston, Texas, United States, 77555-0209|
|Study Chair:||Fannie Smith||University of Texas|